Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the response, safety and tolerability in subjects
receiving the investigational drugs, RAD001 and LBH589. Subjects in Part 1 will receive one
drug for four cycles followed by 4 cycles of the second drug unless they achieve complete
remission. Subjects in a complete remission may receive up to 6 cycles of study drug and will
not receive the next study drug until there is evidence of disease progression. Subjects in
Part 2 will receive both drugs together for at least 2 cycles and up to 13 if tolerated.